Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not Sure Why the Interest in Cyios
Has anyone talked with the CEO? ....A very strange man. He couldn't care less about the stock or it's price. He took the company public to get access to money but never got any ...So he lost interest ,,,no PR's, no growth ...Dropped the PR firm years ago...IMO, there will be nothing happening here ...I sold years ago when he stopped talking to everyone.
Intersystems provides the database/operating system...Quture provides an application as Intersytems many partners also provide application software. Intersystems gathers the data........Quture processes the data.....As I see it.
I agree with you ....I just think it will happen.
?? I do not believe so ....I think when all is said and done, folks here will be very surprised at the investment in manpower and time that Intersystems has put into Quture's software. It's just a matter of time before the ducks are all lined up ....
Could Quture have a better partner? ...Quture and Intersystems are working closer together than ever and for those who can handle the wait time, the will have it's run, IMO.LF's last tweet talks of "excellent progress w/ investor banker meetings".
Big.....I Believe the Intersystems relationship is better than ever ...The medical exchange was a BOPO idea and that has gone the way of BOPO ,,,Looooong term if ever. LF does write long winded PR's(A plus) and at some point he will have to give us a 'Stockholder Update' the should tell us a lot. As to Intersystems buying Quture? ...Somebody will, because that's the only way LF will get his stock sold....I think when LF gets the product line installed and expanding into many locations, especially under the Intersystems umbrella, there may be multiple offers out there. Check Landon's age.........He may want to retire in a year or two ....
penny,,,,Do you understand how the stock market works? There is no way to sell over 2 Billion shares in this stock ......No buyers are waiting in the wings.....The only way management gets Anything for that stock is to sell the company to another ...For that to happen Quture must start selling the software and getting contracts ....IMO Intersystems would be happy to buy Quture should Landon F. want to sell....
I agree LF should issue an update as to progress unfortunately detail news on customers is rarely permitted by them. He certainly seems busy and I take the addition of the new CFO as a real positive... Along with the CFO's investment in the company.
Have you read:http://seekingalpha.com/article/1805682-cvrr-is-back-on-track-with-production-output?source=yahoo
This writer expects the DIV to be over one dollar ..Q3 delivered .44 EPS and CVRR paid out .30 for the Div ....CVRR may want to pay out a lower ratio of profit in Q3 but IMO if the EPS is there the stock goes up whatever the Div is.
Q3 Numbers out ....OK but no growth yet. Murdoch's comments are hopeful for light at the end of the tunnel but no need to buy more stock yet. A 2014 story maybe.
/very littler stock currently on the ASK between .006 and .010 on LVL2
I know the guys at CAA well ....I don't believe they sold any shares ....More than likely they have added shares.
The owners of the shell company, TCLN, that Quture merged into to go public were given shares of Quture for the purchase price. They obviously just dumped them on the market...selling into few buyers. This resulted in a share price drop from .034 to the low of .002 range. That's my understanding...
They now have their product line updated and complete. They have not had revenue growth and a profit....Hopefully 2014 will bring the numbers.
FYI,,,go to the Sentry website and look at the customer lists ....Impressive.
Big,,,,You know what I know. I believe: LF is very close to Intersystems...They want his software on the database of their customers,, The new CFO has invested heavily in Quture (He obviously knows whats going on)The constant meetings, busy schedule etc. of LM will produce results IMO.
CVRR was very open with the downtime in the refining plant and the the obvious drop in revenue and earnings. Yet the stockholders still dumped on the
Q3 news ....Great for me, I was out of the stock ....but in now with 600 shares near the bottom ...
Lots of panic selling today....Picked up a few hundred
Re the Apollo guy ....He didn't deliver and LF got rid of him ....Other than Apollo the guy didn't have much going for him ....
Something to think about.....Why would a guy with a very good job at UBS ,,,making 100K plus or minus ,,a guess,,, quit and go with Quture? ..He obviously knows far more than any posters here as to those potential contracts: "He is already engaged in negotiations with potential joint ventures or strategic alliances of Quture and its subsidiaries. He joined Quture with a significant investment in the Company's stock."
The only reason to leave a career at UBS is for a solid deal somewhere else ....He thinks it's at Quture.....
Quture News
Quture (QUTR) Announces Formation of QualVal Solutions Consulting Subsidiary
Quture's Subsidiary for Consulting Services Bundled With Its QualOptima Product Will Support and Strengthen Sales of Software as a Service (SaaS) to Significantly Enhance Revenue
MarketwiredPress Release: Quture International, Inc. – 33 minutes ago
QUTR 0.004 +0.001
DAYTONA BEACH, FL--(Marketwired - Oct 1, 2013) - Quture International, Inc. (OTCQB: QUTR) today announced the formation of the new subsidiary QualVal Solutions (QualVal). QualVal will provide consulting services bundled with Quture's QualOptima product for software as a service (SaaS). Potential hospital customers of QualOptima have requested Quture's Founder, Landon Feazell, provide consulting expertise in transforming traditional peer review processes to performance measurement to meet and exceed regulatory compliance requirements. Quture's initial customer focus is on hospitals and physician groups. Quture is also forming the consulting subsidiary to expand its customer base beyond providers to the total array of potential customers -- healthcare law firms, health and medical malpractice insurance companies, medical device and equipment manufacturers, electronic medical record (EMR) companies, accountable care organizations (ACO's), health maintenance organizations (HMO's), health information exchanges (HIE's), insurance exchanges, ambulatory surgery centers, employer group plans and health incentive companies, pharmaceutical, proteomics and nutraceutical companies, and large CPA and other consulting firms, and vendors of other technologies that strategically enhance Quture in the market. QualVal is anticipated to provide revenue positive, immediate impact on the Company's bottom line, repeating the previous millions of dollars generated by the Founder's consulting companies.
"Potential customers during initial sales efforts have asked Quture to provide our traditional consulting services to assist them in transitioning from peer review to performance and outcomes measurement," said Landon Feazell, Chairman & CEO of Quture. "We also have extraordinary business opportunities for the QualOptima Connectivity & Analytics System with potential businesses other than healthcare providers that are immediate and lucrative. As Quture introduces its new technology to health care, with the inherent measured pace of early adoption, these other customers provide excellent technology demonstration opportunities as well as immediate revenue. They further allow us to file for new patents as we stage the publication of the results of the Clinical Trial at the University of Miami and Jackson Memorial Hospital, working with Dr. Keith Candiotti."
One initial thrust of QualVal will be to support and enhance licensing the QualOptima Peer Review and Performance & Outcomes Measurement Application, required for hospitals to conduct Focused and Ongoing Professional Practice Evaluation (FPPE-OPPE). The unique capability of QualOptima to permit remote peer review of medical records by physician reviewers facilitates development of user peer panels or for hospitals and hospital systems to use Quture's QualPRO expert physician panels. Quture intends the bundled services of QualVal to initially include contracts with medical device manufacturers that will provide revenue while giving Quture real world experiences to test the proctoring application to complete delivering electronic technology solutions to all requirements of FPPE-OPPE.
Healthcare data and users of these data have been limited almost exclusively to billing data. QualOptima introduces patient-specific scientific risk factors and clinical performance and outcomes data electronically collected from disparate databases through its transformative and disruptive technology on the InterSystems technology platform. Customers of Quture need not only this technology but the expertise and experience of QualVal to strategically know what clinical data to measure, where that data resides, the scientific algorithms to analyze these data and, and most importantly why to measure (measure what you value, value what you measure) and what to do with the information to improve the quality of care and reduce costs, while significantly improving revenue to the bottom-line.
"Hospitals have tons of data, often the wrong data and limited key performance indicators and strategies," said Feazell. "Our customers need our expertise and experience, combined with our new software technology, to more rapidly and effectively meet compliance requirements and realize the power of electronically capturing the data and with analytics embedded in QualOptima. While much has been proposed and hundreds of millions of dollars have been spent on mining 'big data,' the immediate opportunities are to strategically mine data. Quture's expertise for 35 plus years in clinical performance and outcomes analytics is our immediate business advantage. "
Another immediate focus of QualVal will be to consult with healthcare law firms engaged by their clients in qui tam/whistleblower and fraud & abuse cases, as well as firms engaged to proactively prevent costly rack audits while optimizing revenue from efficient and effective billing and practice management software. The QualOptima product is ideal to electronically capture and integrate clinical data in parallel with billing data for litigation analytics. The unstructured data capture and analytics of QualOptima's technology completes the essential tools for litigators and healthcare attorneys for their clients.
QualVal intends to provide consulting services beyond these initial focuses to include optimal clinical processes with risk & fitness factors and performance and outcomes metrics, credentialing and proctoring physicians and clinical practitioners, complication (including hospital acquired conditions) and readmission reductions strategies, analysis of overuse, underuse and misuse, and external clinical auditing, metrics to accomplish strategic planning goals and objectives, and branding strategies to increase patient loyalty and satisfaction and wellness.
"I have been privileged to work with some of the most prominent and proven consultants in American health care, and we are now engaged in the process to recruit them to leadership roles in QualVal as principals," added Feazell. "We are also continuing to explore relationships with other healthcare consulting organizations for strategic alliances. Quture anticipates a series of announcements as core consulting experts contract with QualVal and Quture, as well as announcing specific bundled sales already in negotiations. Quture is making this announcement in anticipation of launching our new website, with the services and solutions portions of the site describing our capabilities and services and to attract customers as well as licensing QualOptima."
Here's the reason to look at SMME .....
Remember it's a spec micro-cap:
"SmartMetric is in discussion with Banks in Asia and Europe concerning partnered role out of its biometric card planned for the early part of 2014. The company is planning limited release for trials in the later part of 2013."
NEWS ....A very large amount of detail info ....note in the last paragraph ....Quture has increased it's addressable market for it's products and services to a far greater degree than in the past ...
Quture (QUTR) Announces Formation of QualVal Solutions Consulting Subsidiary
Quture's Subsidiary for Consulting Services Bundled With Its QualOptima Product Will Support and Strengthen Sales of Software as a Service (SaaS) to Significantly Enhance Revenue
MarketwiredPress Release: Quture International, Inc. – 33 minutes ago
RELATED QUOTES
Symbol Price Change
QUTR 0.004 +0.001
DAYTONA BEACH, FL--(Marketwired - Oct 1, 2013) - Quture International, Inc. (OTCQB: QUTR) today announced the formation of the new subsidiary QualVal Solutions (QualVal). QualVal will provide consulting services bundled with Quture's QualOptima product for software as a service (SaaS). Potential hospital customers of QualOptima have requested Quture's Founder, Landon Feazell, provide consulting expertise in transforming traditional peer review processes to performance measurement to meet and exceed regulatory compliance requirements. Quture's initial customer focus is on hospitals and physician groups. Quture is also forming the consulting subsidiary to expand its customer base beyond providers to the total array of potential customers -- healthcare law firms, health and medical malpractice insurance companies, medical device and equipment manufacturers, electronic medical record (EMR) companies, accountable care organizations (ACO's), health maintenance organizations (HMO's), health information exchanges (HIE's), insurance exchanges, ambulatory surgery centers, employer group plans and health incentive companies, pharmaceutical, proteomics and nutraceutical companies, and large CPA and other consulting firms, and vendors of other technologies that strategically enhance Quture in the market. QualVal is anticipated to provide revenue positive, immediate impact on the Company's bottom line, repeating the previous millions of dollars generated by the Founder's consulting companies.
"Potential customers during initial sales efforts have asked Quture to provide our traditional consulting services to assist them in transitioning from peer review to performance and outcomes measurement," said Landon Feazell, Chairman & CEO of Quture. "We also have extraordinary business opportunities for the QualOptima Connectivity & Analytics System with potential businesses other than healthcare providers that are immediate and lucrative. As Quture introduces its new technology to health care, with the inherent measured pace of early adoption, these other customers provide excellent technology demonstration opportunities as well as immediate revenue. They further allow us to file for new patents as we stage the publication of the results of the Clinical Trial at the University of Miami and Jackson Memorial Hospital, working with Dr. Keith Candiotti."
One initial thrust of QualVal will be to support and enhance licensing the QualOptima Peer Review and Performance & Outcomes Measurement Application, required for hospitals to conduct Focused and Ongoing Professional Practice Evaluation (FPPE-OPPE). The unique capability of QualOptima to permit remote peer review of medical records by physician reviewers facilitates development of user peer panels or for hospitals and hospital systems to use Quture's QualPRO expert physician panels. Quture intends the bundled services of QualVal to initially include contracts with medical device manufacturers that will provide revenue while giving Quture real world experiences to test the proctoring application to complete delivering electronic technology solutions to all requirements of FPPE-OPPE.
Healthcare data and users of these data have been limited almost exclusively to billing data. QualOptima introduces patient-specific scientific risk factors and clinical performance and outcomes data electronically collected from disparate databases through its transformative and disruptive technology on the InterSystems technology platform. Customers of Quture need not only this technology but the expertise and experience of QualVal to strategically know what clinical data to measure, where that data resides, the scientific algorithms to analyze these data and, and most importantly why to measure (measure what you value, value what you measure) and what to do with the information to improve the quality of care and reduce costs, while significantly improving revenue to the bottom-line.
"Hospitals have tons of data, often the wrong data and limited key performance indicators and strategies," said Feazell. "Our customers need our expertise and experience, combined with our new software technology, to more rapidly and effectively meet compliance requirements and realize the power of electronically capturing the data and with analytics embedded in QualOptima. While much has been proposed and hundreds of millions of dollars have been spent on mining 'big data,' the immediate opportunities are to strategically mine data. Quture's expertise for 35 plus years in clinical performance and outcomes analytics is our immediate business advantage. "
Another immediate focus of QualVal will be to consult with healthcare law firms engaged by their clients in qui tam/whistleblower and fraud & abuse cases, as well as firms engaged to proactively prevent costly rack audits while optimizing revenue from efficient and effective billing and practice management software. The QualOptima product is ideal to electronically capture and integrate clinical data in parallel with billing data for litigation analytics. The unstructured data capture and analytics of QualOptima's technology completes the essential tools for litigators and healthcare attorneys for their clients.
QualVal intends to provide consulting services beyond these initial focuses to include optimal clinical processes with risk & fitness factors and performance and outcomes metrics, credentialing and proctoring physicians and clinical practitioners, complication (including hospital acquired conditions) and readmission reductions strategies, analysis of overuse, underuse and misuse, and external clinical auditing, metrics to accomplish strategic planning goals and objectives, and branding strategies to increase patient loyalty and satisfaction and wellness.
"I have been privileged to work with some of the most prominent and proven consultants in American health care, and we are now engaged in the process to recruit them to leadership roles in QualVal as principals," added Feazell. "We are also continuing to explore relationships with other healthcare consulting organizations for strategic alliances. Quture anticipates a series of announcements as core consulting experts contract with QualVal and Quture, as well as announcing specific bundled sales already in negotiations. Quture is making this announcement in anticipation of launching our new website, with the services and solutions portions of the site describing our capabilities and services and to attract customers as well as licensing QualOptima."
Note Re LF ...
Landon F has a Twitter account ... https://twitter.com/Landoni .....He certainly has been busy ...with Intersystems ,,,, who now follows LM's Twitter account ....I would suggest stockholders look in on LM's postings periodically ....I think progress is being made and patience will be rewarded.....
Tell the whole story on .80 ,,,
That was in 2010 when SMME was in settlement talks on the patent case against V/MC ... Oct 20 of 2010 was the deadline for agreement (set by the court) ...The settlement offer price was not met at that time. This time it may be more realistic.
RE the Quture Website ....
Work has started already ,,, a couple weeks ago. It should be close to completion by now I would guess. Intersystems recommended upgrading the website per the IR .....patiently waiting.
Nobody's Buying but the stock has climbed about 200% in the past year .....Wow, all this selling and the stock price goes up....
Bought my first 10K shares in Jan of 2002 @ .20 .....Needless to say I've been waiting too long myself ....But SKVY would have long since been bankrupt and gone without the CEO putting his own money into the company over these many losing years ...He's underwater far more than me ...
Don't expect a high flyer here ....This is strictly a long term play ,,,If you buy, salt it away for the next one to three years, IMO. They sell a big ticket item and the growth in the newest product line has just started this year. There is no reason for this company to attract loads of stock buyers yet ...The sales and a profit will only do that in a future quarterly report....
You got to hold some of this ....even when you've lost patience. More hospitals will be added in time IMO ....And Intersystems is still in the picture...
That $250K could have been used to buy up a good share of the float ...near 10M shares possibly ...
So Far Kapusta is not earning that large payday ...250K should be paying for a long term contract .....Where is the trading volume???
Axle....We all who have followed Sentry for years see the milestone event with these new sales of a finally released new product line. With no IR Group hired and promoting the company and no Quarterly filed showing an operating profit or huge sales growth, the stock will not look attractive yet ....If Murdoch can build on his success so far it will eventually pay off...The stock will run .....He may have to hire an IR promoter ...K
IMO, These contracts may come on very fast ....meaning by year end Quture will have many hospitals and some other related non-hospital deals that the revenue stream will be ever increasing. Sub-penny will be long gone and many selling in this range will buy back at higher prices or just sit and watch it grow, waiting for the pullback that does not occur. There will be much interest by the medical software players in buying this company. The premium will be high in that case. Time will tell.........Keep in mind that every hospital pays every year ....a continual revenue stream ...New hospitals add to that total ...
NO ,,,,Any buyout happens only when Landon Feazell agrees to sell his 85% of the shares ....That will only happen after he grows the business and gets the stock much higher than recent sub-penny prices....My guess is if he is successful it will be .15 to .25 ....
Not only is it 85% insider owned, but totally in the hands of LF, the CEO .....He has extreme restrictions on selling any stock.It spans 20 years. Had he sold any there would have been SEC Filings. There were none.
Landon Feazell's only way to get the value of his stock position is to sell the company after having succeeded in growing the business. Given LF's age @ 69 we will not be waiting forever.
Expect the company to be bought out by a major player in the business when LF gets there ,,,,,,,,,for a large premium on the stock price.
News ............A Sale of the New Video Railway
NOTE: The "Worlds Largest Video Integrator" Means SKVY's marketing partner ,, TYCO
Sentry Technology Receives VideoRailway(TM) Order
Accesswire7 hours ago
Email
Print
RELATED QUOTES
Symbol Price Change
SKVY 0.03 0.00
RONKONKOMA, NY, July 24, 2013 - (eTeligis via ACCESSWIRE) - Sentry Technology Corporation (OTC Pink: SKVY) today announced the receipt of an order for VideoRailway(TM) (VR) systems from the world's largest video integrator, for installation in South Africa. VideoRailway is the company's newest traveling camera technology featuring an HD/IP, pan tilt and zoom (PTZ) camera that travels along a rail suspended from the ceiling. A combination of straight and curved rail segments can create a "U" as well as a completely closed loop. By turning corners, a single camera views a much larger area with minimal additional expense.
"We are pleased to receive the first VideoRailway order from our largest video systems integrator," said Peter Murdoch, President and CEO of Sentry Technology. "This order will be shipped in advance of the official launch of the VR system scheduled for early September."
Duh ....The price of the stock tells you that ....Any purchase of a sub-penny stock has only a story of a possibility ....not revenue.
That's the point froggie ....There's been NO news but the stock goes from zero trading for years and suddenly Quadruples in price ...without a press release to drive it ....Just think about it for a while..
Still has a lot more room to go up ...........